Navigation Links
arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
Date:7/26/2011

ROTTERDAM, Netherlands, GHENT, Belgium, and PRINCETON, N.J., July 26, 2011 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT® Technology.

arGEN-X's SIMPLE Antibody™ platform is unique in providing human variable regions of unprecedented diversity, allowing the rapid selection of antibodies with superb functional potency. In under two years, these attributes have already been validated preclinically in seven in vivo and ex vivo models, highlighting the productivity of the technology.

POTELLIGENT® Technology is a clinically validated approach to producing monoclonal antibodies (mAbs) with significantly enhanced antibody-dependent cellular cytotoxicity (ADCC) and tumor cell killing activity. By combining the power of the SIMPLE Antibody™ platform with POTELLIGENT® Technology, arGEN-X expects to increase the intrinsic potency of these mAbs even further. Under this license agreement, arGEN-X will apply POTELLIGENT® Technology to its own novel mAbs addressing cancer and inflammatory disorders and will offer antibodies encompassing both technologies to its commercial partners.

Commenting on today's announcement, Tim Van Hauwermeiren, CEO of arGEN-X, said: "We are applying our proprietary SIMPLE Antibody™ technology to targets where a selectively potent antibody interaction works in concert with effector function to mediate optimal therapeutic effects. The extraordinary diversity of antibodies generated from our platform allows us to preferentially select leads with only the highest quality functional properties. Combining such superior variable regions with constant regions enhanced by the validated POTELLIGENT® Technology supports our strategy of creating highly differentiated, competitive antibody products."  

Dr. Yasunori Yamaguchi, President and CEO of BioWa, commented further: "We are pleased to have this arrangement with an innovative company such as arGEN-X.  The SIMPLE Antibody™ platform and POTELLIGENT® Technology are very complementary and promise to enable important increases in therapeutic antibody potency."

About arGEN-X - www.arGEN-X.com

arGEN-X aspires to be a transforming force in the therapeutic monoclonal antibody arena. Its SIMPLE Antibody™ platform is unmatched in its ability to blanket human disease targets with functional antibodies, including targets that cannot be accessed by conventional discovery platforms. SIMPLE Antibodies™ have human sequences and structures, femtomolar affinities and potencies as well as excellent manufacturability. The characteristics of SIMPLE Antibodies™ provide arGEN-X and its partners with unprecedented choice in developing differentiated therapeutic mAb products.

arGEN-X™ and SIMPLE Antibody™ are deposited trademarks of arGEN-X BV.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering

About POTELLIGENT® Technology

POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics.  POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell.  Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT® antibodies are being investigated in human clinical trials. Earlier this year, Kyowa Hakko Kirin submitted a New Drug Application in Japan for KW-0761, a POTELLIGENT® antibody for the treatment of Adult T-cell Leukemia-Lymphoma (ATL).

About BioWa

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of the AccretaMab® platform. The AccretaMab® platform consists of POTELLIGENT® and COMPLEGENT® Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities.  BioWa is offering POTELLIGENT® and COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies.  Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases.  For more information about BioWa, visit its web site at http://www.biowa.com.

POTELLIGENT®, COMPLEGENT®, and AccretaMab® are the trademarks of Kyowa Hakko Kirin Co., Ltd.  All rights are reserved.  


'/>"/>
SOURCE BioWa, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
2. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
3. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
4. NuMe Health Announces Closing of Series A-1 Financing Round
5. Amgen Announces Webcast of 2011 Second Quarter Financial Results
6. Lanx, Inc. Announces Aspen™ Spinous Process Fixation System Clinical Data at IMAST
7. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
8. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
9. SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved
10. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
11. Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Calif., Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) ... ended December 31, 2015. The Company also filed its Quarterly ... year 2016 with the Securities and Exchange Commission today. ... 31, 2015 --> --> ... increased $2.6 million, or 95%, to $5.4 million from $2.8 ...
(Date:2/11/2016)...  Kindred Biosciences, Inc. (NASDAQ: KIN ), a ... of pets, today announced the submission to FDA of ... Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline ... for the control of pyrexia (fever) in horses were ... --> The Chemistry, Manufacturing, and Controls ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From March 4 through 6, ... Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. , ... condition of hyperhidrosis (excessive sweating) and its treatment options. Specifically, the company will ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking has completed its ... on February 6th & 7th, 2016 according to kicking coach Michael Husted. , “This ... to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party ...
(Date:2/11/2016)... , ... February 11, 2016 , ... The book, “Computers ... IT services, what questions to ask your IT consultant before signing a contract and ... your computer network. , “With companies relying heavily on e-mail and technology, it’s more ...
(Date:2/11/2016)... AZ (PRWEB) , ... February 11, 2016 , ... As ... with support of the Million Dollar Round Table Foundation (MDRTF), has gifted $10,000 to ... according to Colleen’s Dream Foundation President Billy Cundiff. , “We are honored to support ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual meeting ... Congress (WMIC), will be held in New York City, NY on September 7 ... The congress will highlight and emphasize how imaging reveals a greater understanding of ...
Breaking Medicine News(10 mins):